METiS Pharma Appoints Mark Herbert as Chief Business Officer
03 Mar 2025 //
PR NEWSWIRE
METIS Phase 3 Trial Met Primary Endpoint, Demonstrating a Significant Extension
27 Mar 2024 //
BUSINESSWIRE
METiS Announces License Agreement with Evopoint Biosciences
06 Jan 2023 //
BUSINESSWIRE